AstraZeneca And Ionis ATTR Ambitions Boosted
Efficacy of Eplontersen Maintained For 66 Weeks
Executive Summary
The companies are hoping that new data on recently-filed eplontersen will boost the drug's chances of challenging Alnylam’s Amvuttra and Onpattro.